 There has been interest in the drug for the potential treatment of prostate cancer as well.As of 2017, it is in phase II clinical trials for acne vulgaris.Dimethylcurcumin is an androgen receptor (AR) inhibitor and shows strong and specific antiandrogenic activity "in vitro" (e.g., against LNCaP cell growth) at sufficiently high concentrations.